FDA Approves Igalmi for Agitation | Psychiatric News
Apr 25, 2022 · The Food and Drug Administration (FDA) in April approved a sublingual formulation of dexmedetomidine under the brand name of Igalmi for the treatment of agitation associated with schizophrenia or bipolar I or II disorder. Dexmedetomidine was previously approved in intravenous form for anesthesia.
Warnings of new deadly chemical in street drug supply : NPR
May 29, 2024 · Public health officials say Mexican cartels and drug gangs inside the U.S. are mixing a dangerous chemical sedative called medetomidine into fentanyl and other drugs sold on the street. The...
UNC School of Medicine, BioXcel Therapeutics Team Up to Tackle …
Oct 15, 2024 · U.S. Department of Defense awarded $2.8 million to UNC Institute for Trauma Recovery researchers led by Samuel McLean, MD, to test the safety and efficacy of BXCL501 – sublingual dexmedetomidine created by BioXcel Therapautics for treating acute stress reaction symptoms and preventing posttraumatic stress. Sam McLean, MD, MPH. Each year ...
Dexmedetomidine or Propofol for Sedation in Mechanically …
Feb 2, 2021 · Guidelines currently recommend targeting light sedation with dexmedetomidine or propofol for adults receiving mechanical ventilation. Differences exist between these sedatives in arousability,...
Use of dexmedetomidine in critical-ill patients: is it time to look …
Aug 29, 2023 · Dexmedetomidine is an alpha-2 (ɑ2) adrenergic receptor and imidazoline type 2 receptor agonist that received Food and Drug Administration (FDA) approval in 1999 as a sedative and analgesic that also reduces stress, anxiety, and the risk of …
Association of Dexmedetomidine With New-Onset Atrial …
Apr 25, 2023 · This cohort study investigates the association of dexmedetomidine use with risk of new-onset atrial fibrillation among patients who are critically ill.
Study finds use of sedative dexmedetomidine decreases cerebral ...
Nov 4, 2024 · The study assessed the effect of the sedative dexmedetomidine (Dex) on patients undergoing CAS. It found that only 11% of patients receiving Dex developed cerebral hyperperfusion, compared to 38%...
BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine …
Apr 6, 2022 · BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults ...
Efficacy and safety of dexmedetomidine for analgesia and
Oct 16, 2023 · Dexmedetomidine, a highly selective alpha-2-adrenoreceptor agonist, has piqued interest as a viable alternative for neonates, owing to its potential analgesic and neuroprotective attributes. We...
Dexmedetomidine: present and future directions - PMC
Dexmedetomidine is a potent, highly selective α-2 adrenoceptor agonist, with sedative, analgesic, anxiolytic, sympatholytic, and opioid-sparing properties. Dexmedetomidine induces a unique sedative response, which shows an easy transition from sleep ...